SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

ALR Technologies (ALRT)

ALRT RSS Feed
Add ALRT Price Alert      Hide Sticky   Hide Intro
Moderator: Sam'd'Mil, makinezmoney, knowmystuff, big green tractor, rhardy270, Pi_Sky2017
Search This Board: 
Last Post: 10/19/2017 11:24:59 AM - Followers: 185 - Board type: Free - Posts Today: 9







OTCBB : $ALRT

 





FDA APPROVAL NEWS ON SEPTEMBER 19, 2017


 



ALR Technologies, Inc. (OTCBB: ALRT) is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases.
ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website.
Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their HEDIS goals.
Currently, the company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.

ALRT received FDA clearance for the HeC system in October, 2011.  Company CEO, Sidney Chan, commented, "We are pleased to reach this milestone and are
eager to introduce to market this cross-platform technology. The HeC System represents a breakthrough for clinician/patient communication to enhance disease
management and improve health outcomes. The System provides the potential to achieve significant savings to the US healthcare system through enhanced adherence to
care plans. In anticipation of the FDA clearance, we have been cultivating relationships with manufacturers of diabetes test supplies and insurance
companies to help facilitate a successful launch."

President and COO Lawrence Weinstein added, "Diabetes management represents the initial chronic illness application for HeC and we plan to
expand upon that platform in 2012. A first-to-market product, the HeC System bridges gaps in current remote monitoring systems in a manner that is
efficient, effective and affordable. We anticipate a strong demand based upon our present relationships with industry leaders. Given the flexibility of the HeC System,
the potential is enormous. This FDA clearance is a major stride in our commitment to building long-term shareholder value as there is a wide spectrum of chronic
diseases which the HeC platform can be deployed to improve outcomes and contain costs."



 




HOW HEALTH e-CONNECT WORKS



https://youtu.be/S7TFIZ3mcG4


 


 


Sidney S. Chan, CEO and Chairman

Mr. Chan has been involved in managing ALR Technologies since August 1997. Since then, he has played a pivotal role in the evolution of ALR Technologies into a public company. Mr. Chan has been extensively involved in the company's finances and product development. 

Mr. Chan is an engineer who obtained his Bachelor of Engineering (Mining) degree with the distinction in Mineral Economics from McGill University in 1973.

Larry Weinstein, President and Chief Operating Officer

Mr. Weinstein joined ALRT in July 2010, bringing over 25 years of medical device development and management experience from organizations such as Cordis Corporation, DHD Healthcare and PARI Respiratory Equipment. 

Mr. Weinstein received a Bachelor of Science in Chemical Engineering degree from Rensselaer Polytechnic Institute. He earned both a Master of Science degree in Industrial Engineering and an MBA from the University of Miami.

William S. Smith, Director, Commercial Strategy and External Affairs

William S. Smith has worked at senior levels in the private sector and in government. He has more than a decade of experience in healthcare. He served as Managing Director at NSI, a Washington-based government affairs firm. His clients have included major pharmaceutical and biotechnology companies where Mr. Smith has provided strategic advice on government affairs challenges.

Mr. Smith spent ten years at Pfizer, Inc, where he was Vice President for U.S. Public Affairs and Policy. In that role, Smith was the lead advisor on U.S. policy issues to Pfizer's major commercial businesses in the United States. Smith also ran Pfizer's state government affairs group, one of the largest such groups in corporate America.

Mr. Smith previously worked in government where he was on the staff of two Governors in Massachusetts, was a leadership aide to the Republican Leadership in the U.S. House of Representatives, and was a senior aide in the White House Office of National Drug Control Policy under President George H.W. Bush.

Mr. Smith is a graduate of Georgetown University and has a Masters in Politics from the Catholic University of America.

Jerome P. Hickey, Director of Sales and Marketing

Mr. Hickey was most recently National Account Manager at Medicis Pharmaceutical Company, working with many of the largest healthcare payers in the U.S. Prior to Medicis, Mr. Hickey had extensive experience in sales at Pfizer, Inc., rising from a sales representative to assume such positions as Director of Managed Markets Training and Regional Director of Managed Markets for the New York region, one of Pfizer's most important sales regions. Mr. Hickey was responsible for delivering over 1.4 billion dollars in gross revenue at Pfizer.

Kent Stoneking, Pharm. D., CDE, Director, Diabetes Care Facilitation

Dr. Stoneking is a Certified Diabetes Educator (CDE) who has gained extensive, hands-on experience working with a network of internal medicine and family practice physicians to assist patients with diabetes education and self-management training. He received his Doctor of Pharmacy from the University of Tennessee and is an affiliate member of the American Diabetes Association and the American Pharmacists Association.  Dr. Stoneking is Chair of Pharmacy Practice at Union University School of Pharmacy, Jackson, Tennessee.

Dr. Alfonso Salas, Director

Dr. Salas graduated with distinction from Universidad Metroplitana of Barranquilla, Colombia in 1983 with a Doctor of Medicine degree. He began practicing in Santa Marta, Columbia in rural medical facilities and the opened a private practice in 1984. He then worked as a physician with a number of shipping companies and became Medical Director in the office of the Ministry of Social Security and Labor of Columbia in 1991 doing medical assessments for work related accidents. In 1993 Dr. Salas was appointed Director of a Medical Service Plan of Columbia and with a support staff of more than thirty people, maintained a caseload, provided assessment procedures and referral services to hospitals, clinics, and specialists and organized and monitored clinical trials and clinical research in the pharmaceutical and medical field. Since 1995 Dr. Salas has operated his own business in Vancouver, British Columbia, providing medical based consulting services for corporations with a focus on budgeting, research and medical services.

Kenneth Robulak, Director

From December 14, 1999 to January 31, 2001, Mr. Robulak was a member of the ALRT board of directors and from April 4, 2000 to January 31, 2001 Mr. Robulak was ALRT's chief financial officer, secretary, treasurer and vice president.  Mr. Robulak resigned as an officer and director on January 31, 2001. At the time of his resignation, Mr. Robulak did not have any disagreements with ALRT relating to our operations, policies, or practices. Since August 2005, Mr. Robulak has served as a Director of Belle Harbor Owners Association, a not for profit company in Clearwater Beach, Florida. Since July 2007, Mr. Robulak has worked as a marketing consultant to Teco Metal Products, LLC, a technology based manufacturing Company with operations in Dallas, Texas and Guadalajara, Mexico . Mr. Robulak earned a Bachelor of Commerce degree in finance and marketing and is a Fellow of the Institute of Canadian Bankers.

 


Diabetes information:

CDC Fact Sheet:  http://www.alrt.com/assets/images/library/CDC%20fact%20sheet-%2040percent%20Reduction%20Proof%20Text.pdf

Additional Reading: 

One in 10 Adults to Have Diabetes by 2030 as Cases Surge 90%, Report Says (Bloomberg)
Diabetes forecast to hit one in 10 adults by 2030 (Reuters)
Diabetes News Highlights Global Pandemic and Millions of Dollars Wasted (MarketWatch)
Web Black Market in Diabetic Supplies Costs Government $200m (The Daily Beast)

(More to Come...)

 


LATEST NEWS:

February 04, 2013 - ALR Technologies Letter to Shareholders
January 28, 2013 - ALR Technologies Appoints Dr. Kent Stoneking as Director of Diabetes Care Facilitation
January 22, 2013 - ALR Technologies Releases Video on how ALRT Diabetes Care Facilitators Use the Health-e-Connect System (to Improve Outcomes and HEDIS Scores)
January 14, 2013 - ALR Technologies Releasing a Marketing Video with the Commercial Launch of the Health-e-Connect system for Diabetes Care
January 07, 2013 - ALR Technologies Inc. Announces Director of Sales and Marketing

News Archive:  http://www.alrt.com/about/newsarchive


CLINICAL TRIALS:

Effect of Internet Therapeutic Intervention on A1C Levels in Patients With Type 2 Diabetes Treated With Insulin


VIDEOS:









         

A complete list of videos for viewing is located at:  http://www.youtube.com/user/ALRTechnologies?feature=watch


ANALYST REPORTS:

Taglich Brothers:  PowerPoint format:  http://www.slideshare.net/ALRTechnologies/alr-technologies-taglich-brothers-analyst-report

or


download the PDF file by clicking the image.


SEC FILINGS:  http://secfilings.com/SearchResults.aspx?ticker=alrt

SHARE STRUCTURE:

Outstanding Shares:  233,977,909
Float:  approximately 109,000,000
Insiders Holdings:  approximately 60%
(information as of Feb. 18, 2013, per Yahoo Finance)
 
WEBISTE:  www.alrt.com

CONTACT INFORMATION:

ALR Technologies, Inc.
7400 Beaufont Springs Dr.   Suite 300
Richmond, VA     23225
Tel: 804-554-3500
Email: contact@alrt.com

 

 

SureTrader
Interactive Brokers Advertisement
ALRT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ALRT News: Current Report Filing (8-k) 10/18/2017 12:36:02 PM
ALRT News: Current Report Filing (8-k) 10/03/2017 02:17:00 PM
ALRT News: Current Report Filing (8-k) 09/22/2017 06:02:10 AM
News News Alert: Current Report Filing (8-k) 10/18/2017 12:36:02 PM
PostSubject
#5574  Sticky Note Sidney's responses buzzabby 09/27/17 08:52:20 PM
#3763  Sticky Note First, we offered our Diabetes Management System, without GS1 09/21/17 11:16:23 PM
#3104  Sticky Note Sidney Chan emailed me. They plan to market Type0neg 09/20/17 04:52:47 PM
#2174  Sticky Note $ALRT tape-reading level-1 bid/ask price_&_size_w/Time+Sales. dazetrader 09/20/17 01:05:35 AM
#985  Sticky Note NEWS: Massive runner right now...... WOooooooooooooooooooo makinezmoney 09/19/17 10:05:12 AM
#6302   Yeah; remember one short month-ago it jumped 100X OBE 10/19/17 11:24:59 AM
#6301   On the bid why not don estaban 10/19/17 11:09:07 AM
#6300   This stock has a lot to offer, I stockstalk09 10/19/17 10:35:49 AM
#6299   It's-low-VOL but-it's-trading. I'm trying to add @ .036 [ OBE 10/19/17 10:12:24 AM
#6298   Just a slow start Thrashing21 10/19/17 10:01:22 AM
#6297   Why is this not trading? lyokoboy 10/19/17 09:41:33 AM
#6296   My sentiments exactly. Excellent reply! penguin007 10/19/17 09:13:21 AM
#6295   I absolutely love ure avatar think there stokbrokin 10/19/17 01:56:14 AM
#6294   I have spent all night watching everything on buzzabby 10/19/17 01:23:37 AM
#6293   The point I was trying to make is Cache 10/18/17 06:21:16 PM
#6292   Lol, would you want them? Neophius 10/18/17 06:10:36 PM
#6291   Your theories are ridiculous. I’m not really that complicated. Neophius 10/18/17 06:10:11 PM
#6290   You mean I'll be able to buy the Cache 10/18/17 06:05:18 PM
#6289   good point, it will be in 2019. GrandeS 10/18/17 05:54:03 PM
#6288   So no employees just contractor/advisers restripe 10/18/17 05:51:38 PM
#6287   Oh, they’ll be above $4 a share for Neophius 10/18/17 05:50:50 PM
#6286   Good post BooDog. I think they are GrandeS 10/18/17 05:46:06 PM
#6285   ALRT is filing things to catch up... CRAZY $$$ 10/18/17 05:42:08 PM
#6284   Nothing in the share structure changed during the buzzabby 10/18/17 05:41:31 PM
#6283   Except there’s no proof of that provided as Neophius 10/18/17 05:39:10 PM
#6282   He has 16 full time on contract and buzzabby 10/18/17 05:31:43 PM
#6281   Ha, every board says that. Broken clock and all. Neophius 10/18/17 04:21:41 PM
#6280   Pretty sure the SEC will tell ALRT to BooDog 10/18/17 04:00:58 PM
#6279   Who..do..you..think..is..worse? One who sinks-his-money into-a-stock and then ta OBE 10/18/17 03:52:36 PM
#6278   But don't-you-think he-would-have-made-some-hay when the pps jumped 100X? OBE 10/18/17 03:41:52 PM
#6277   Well I hope so he is the only restripe 10/18/17 03:32:19 PM
#6276   Ah, good ole echo chamber. I love when promoters Neophius 10/18/17 03:29:13 PM
#6272   20 Million invested and 97.5 percent ownership. buzzabby 10/18/17 02:52:53 PM
#6269   Hey, you might prove to be correct. Neophius 10/18/17 02:06:39 PM
#6268   So incorrect. There may be similar web based GrandeS 10/18/17 02:02:23 PM
#6266   Once they announce commercial partners and co-marketers that buzzabby 10/18/17 01:59:35 PM
#6264   Troll implies untruth or deception. I engage in neither. Neophius 10/18/17 01:54:07 PM
#6263   An experienced abrasive troll yes Nan Doe 10/18/17 01:45:35 PM
#6262   No, it’s a comparable product. FDA clearance Neophius 10/18/17 01:44:44 PM
#6261   SEC 8-K filed today, from yesterdays news. BooDog 10/18/17 01:44:24 PM
#6260   Actually, you are not very knowledgeable. You GrandeS 10/18/17 01:42:03 PM
#6259   I like it! I-liked-reading Jimmie-Breslin and watching Jon-Stewart. OBE 10/18/17 01:33:39 PM
#6258   Not much meat to that 8k, everything was Jmann33 10/18/17 01:32:11 PM
#6257   I’m certainly abrasive, but I’m not a troll. Experienced. Trade Neophius 10/18/17 01:29:21 PM
#6256   lol he's just a troll don't mind him. Nan Doe 10/18/17 01:23:33 PM
#6255   I-don't-understand-the-disclaimer-used-by-so-many that "my posts are my own-opi OBE 10/18/17 01:21:29 PM
#6254   LOL sounds like me onco 10/18/17 01:13:28 PM
#6253   Be realistic! I'm averaging-down because I-have-faith in ALRT OBE 10/18/17 01:13:26 PM
#6252   Based on that trend, wait for it to Neophius 10/18/17 01:04:35 PM
#6251   Looking good here! Thrashing21 10/18/17 01:00:44 PM
#6250   I've-bought-in-@ .129, .062, .059, .056, .05, .046, .042 OBE 10/18/17 12:57:18 PM
#6249   https://ih.advfn.com/p.php?pid=ihm_newsArtView&article=75889384&symbol=NO%5EALRT Nan Doe 10/18/17 12:54:37 PM
#6248   Good 8k! No worry about halt Mr Wowza 10/18/17 12:53:23 PM
#6247   I don’t advise entry or exit positions, sorry. djran99 10/18/17 12:52:42 PM
#6246   Is .04 good entry point? don estaban 10/18/17 12:52:04 PM
PostSubject